Last reviewed · How we verify
Salbutamol + Tiotropium
Salbutamol is a short-acting beta-2 agonist that rapidly opens airways, while tiotropium is a long-acting anticholinergic that provides sustained bronchodilation for chronic airway obstruction.
Salbutamol is a short-acting beta-2 agonist that rapidly opens airways, while tiotropium is a long-acting anticholinergic that provides sustained bronchodilation for chronic airway obstruction. Used for Chronic obstructive pulmonary disease (COPD) maintenance and symptom relief, Asthma maintenance and acute symptom relief.
At a glance
| Generic name | Salbutamol + Tiotropium |
|---|---|
| Also known as | Ventolin, Spiriva |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Drug class | Combination bronchodilator (short-acting beta-2 agonist + long-acting anticholinergic) |
| Target | Beta-2 adrenergic receptor (salbutamol); Muscarinic M3 receptor (tiotropium) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Salbutamol works by stimulating beta-2 adrenergic receptors on airway smooth muscle, causing rapid relaxation and bronchodilation for acute symptom relief. Tiotropium blocks muscarinic M3 receptors on airway smooth muscle, providing long-acting sustained bronchodilation. Together, they provide both rapid relief and maintenance control of airway obstruction in chronic obstructive pulmonary disease (COPD) and asthma.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance and symptom relief
- Asthma maintenance and acute symptom relief
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Tachycardia
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
- Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists
- Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma (NA)
- Efficacy of Intermittent Tiotropium in Early Childhood Wheezing (PHASE4)
- Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD
- Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients. (PHASE4)
- A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol. (PHASE3)
- Tiotropium/Salmeterol Inhalation Powder in COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salbutamol + Tiotropium CI brief — competitive landscape report
- Salbutamol + Tiotropium updates RSS · CI watch RSS
- IRCCS Azienda Ospedaliero-Universitaria di Bologna portfolio CI